CO2017005732A2 - Compuestos de dihidropirimidin-2-ona y sus usos médicos - Google Patents

Compuestos de dihidropirimidin-2-ona y sus usos médicos

Info

Publication number
CO2017005732A2
CO2017005732A2 CONC2017/0005732A CO2017005732A CO2017005732A2 CO 2017005732 A2 CO2017005732 A2 CO 2017005732A2 CO 2017005732 A CO2017005732 A CO 2017005732A CO 2017005732 A2 CO2017005732 A2 CO 2017005732A2
Authority
CO
Colombia
Prior art keywords
dihydropyrimidin
compounds
medical uses
medical
symbol
Prior art date
Application number
CONC2017/0005732A
Other languages
English (en)
Inventor
Masahiro Yokota
Taku Ikenogami
Eiichi Watanabe
Noriyoshi Seki
Takayuki Sakai
Shingo Fujioka
Makoto Shiozaki
Katsunori Suwa
Yosuke Ogoshi
Masato Noguchi
Katsuya Maeda
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of CO2017005732A2 publication Critical patent/CO2017005732A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C265/00—Derivatives of isocyanic acid
    • C07C265/02—Derivatives of isocyanic acid having isocyanate groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/12—Organo silicon halides

Abstract

Un compuesto de Fórmula [I] o una de sus sales farmacéuticamente aceptables: (Fig. I) donde cada símbolo se define como en la memoria descriptiva.
CONC2017/0005732A 2014-12-12 2017-06-09 Compuestos de dihidropirimidin-2-ona y sus usos médicos CO2017005732A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014251771 2014-12-12
PCT/JP2015/084791 WO2016093342A1 (ja) 2014-12-12 2015-12-11 ジヒドロピリミジン－２－オン化合物およびその医薬用途

Publications (1)

Publication Number Publication Date
CO2017005732A2 true CO2017005732A2 (es) 2017-08-31

Family

ID=56107519

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0005732A CO2017005732A2 (es) 2014-12-12 2017-06-09 Compuestos de dihidropirimidin-2-ona y sus usos médicos

Country Status (34)

Country Link
US (4) US10196363B2 (es)
EP (2) EP3231793B1 (es)
JP (3) JP6757565B2 (es)
KR (1) KR102551018B1 (es)
CN (1) CN107001286B (es)
AR (1) AR102972A1 (es)
AU (1) AU2015362394C1 (es)
BR (1) BR112017010471B1 (es)
CA (1) CA2965804C (es)
CL (1) CL2017001467A1 (es)
CO (1) CO2017005732A2 (es)
CY (1) CY1122971T1 (es)
DK (1) DK3231793T3 (es)
ES (1) ES2787700T3 (es)
HR (1) HRP20200584T1 (es)
HU (1) HUE048503T2 (es)
IL (2) IL251940B (es)
LT (1) LT3231793T (es)
ME (1) ME03760B (es)
MX (1) MX371128B (es)
MY (1) MY193671A (es)
NZ (1) NZ731607A (es)
PE (1) PE20171119A1 (es)
PH (1) PH12017501071A1 (es)
PL (1) PL3231793T3 (es)
PT (1) PT3231793T (es)
RS (1) RS60352B1 (es)
RU (1) RU2770061C2 (es)
SA (1) SA517381678B1 (es)
SG (2) SG11201703885TA (es)
SI (1) SI3231793T1 (es)
TW (2) TWI690515B (es)
WO (1) WO2016093342A1 (es)
ZA (1) ZA201703976B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2770061C2 (ru) * 2014-12-12 2022-04-14 Джапан Тобакко Инк. Соединения дигидропиримидин-2-она и их медицинское применение
CN106496008A (zh) * 2016-10-20 2017-03-15 上海毕得医药科技有限公司 一种合成4‑(4‑氯苯基)环己酮的方法
JP7200005B2 (ja) 2018-02-28 2023-01-06 日本たばこ産業株式会社 飽和環縮合ジヒドロピリミジノン又はジヒドロトリアジノン化合物及びその医薬用途
CA3087994A1 (en) * 2018-02-28 2019-09-06 Japan Tobacco Inc. 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof
CN110294762B (zh) * 2019-06-14 2020-12-15 深圳市疾病预防控制中心（深圳市卫生检验中心、深圳市预防医学研究所） 检测米酵菌酸中毒的人工抗原及应用
WO2021149786A1 (en) 2020-01-24 2021-07-29 Japan Tobacco Inc. Methods of treating cancer using dihydropyrimidin-2-one compounds
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485107A (en) * 1982-11-01 1984-11-27 Janssen Pharmaceutica N.V. [[Bis(aryl)methylene]-1-piperidinyl]alkyl-pyrimidinones
TWI423819B (zh) * 2005-12-22 2014-01-21 Hydra Biosciences Inc 用於調節ｔｒｐａ１功能之化合物
DE102006031314A1 (de) * 2006-07-01 2008-01-03 Bayer Healthcare Aktiengesellschaft Verwendung von 1,4-Diaryl-dihydropyrimidin-2-on-Derivaten zur Behandlung der pulmonalen arteriellen Hyptertonie
CA2694057A1 (en) 2007-08-09 2009-02-12 F. Hoffmann-La Roche Ag Benzoyl-piperidine derivatives as dual modulators of the 5-ht2a and d3 receptors
US20110201634A1 (en) * 2008-06-13 2011-08-18 Delhi University Dihydropyridimidinone compounds for the treatment of cardiovascular diseases and process for preparing the same
MX2013012542A (es) * 2011-04-28 2013-11-20 Japan Tobacco Inc Compuestos de amida y aplicacion farmaceutica para el mismo.
EP2682389A1 (en) 2012-07-02 2014-01-08 Commissariat A L'energie Atomique Et Aux Energies Alternatives Dihydropyrimidin-2(1H)-ones and dihydropyrimidin-2(1H)-thiones as inhibitors of sodium iodide symporter
WO2014062938A1 (en) * 2012-10-19 2014-04-24 Bristol-Myers Squibb Company Rory modulators
US20160137639A1 (en) 2012-10-26 2016-05-19 Japan Tobacco Inc. Triazole-isoxazole compound and medical use thereof
CN103113308B (zh) * 2013-01-25 2014-11-19 浙江大学 一种制备二氢嘧啶酮衍生物的方法
MA41148A (fr) 2014-12-12 2017-10-17 H Lundbeck As Procédé de fabrication d'idalopirdine
RU2770061C2 (ru) * 2014-12-12 2022-04-14 Джапан Тобакко Инк. Соединения дигидропиримидин-2-она и их медицинское применение
CN107835810A (zh) 2014-12-12 2018-03-23 瑞格纳西制药有限公司 作为hdac1/2抑制剂的哌啶衍生物
TW201630881A (zh) 2014-12-12 2016-09-01 Ｈ 朗德貝克公司 用於生產艾達魯吡啶之方法
WO2016091346A1 (en) 2014-12-12 2016-06-16 Merck Patent Gmbh Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with an egfr inhibitor

Also Published As

Publication number Publication date
RU2770061C2 (ru) 2022-04-14
IL251940B (en) 2021-06-30
JP6757565B2 (ja) 2020-09-23
US20210130300A1 (en) 2021-05-06
SG10202010291VA (en) 2020-11-27
AR102972A1 (es) 2017-04-05
CN107001286A (zh) 2017-08-01
AU2015362394C1 (en) 2021-01-28
MY193671A (en) 2022-10-24
BR112017010471B1 (pt) 2024-02-27
CN107001286B (zh) 2020-07-07
RU2017124423A3 (es) 2019-08-13
RS60352B1 (sr) 2020-07-31
EP3231793A4 (en) 2018-09-19
EP3231793A1 (en) 2017-10-18
WO2016093342A1 (ja) 2016-06-16
HUE048503T2 (hu) 2020-07-28
BR112017010471A2 (pt) 2017-12-26
SA517381678B1 (ar) 2021-12-14
JP2016113455A (ja) 2016-06-23
TWI690515B (zh) 2020-04-11
AU2015362394A1 (en) 2017-05-25
CY1122971T1 (el) 2021-10-29
US10196363B2 (en) 2019-02-05
US20190359575A1 (en) 2019-11-28
PT3231793T (pt) 2020-05-06
IL283335B (en) 2022-04-01
PE20171119A1 (es) 2017-08-08
IL251940A0 (en) 2017-06-29
RU2017124423A (ru) 2019-01-15
CA2965804A1 (en) 2016-06-16
US20230373932A1 (en) 2023-11-23
NZ731607A (en) 2024-03-22
KR20170090497A (ko) 2017-08-07
MX2017007577A (es) 2017-09-28
PL3231793T3 (pl) 2020-07-27
SG11201703885TA (en) 2017-06-29
SI3231793T1 (sl) 2020-07-31
ZA201703976B (en) 2019-06-26
TW201639820A (zh) 2016-11-16
JP2020200339A (ja) 2020-12-17
DK3231793T3 (da) 2020-05-11
TWI739206B (zh) 2021-09-11
ES2787700T3 (es) 2020-10-16
CA2965804C (en) 2023-10-10
MX371128B (es) 2020-01-17
TW202012377A (zh) 2020-04-01
EP3744713A1 (en) 2020-12-02
IL283335A (en) 2021-07-29
CL2017001467A1 (es) 2018-01-05
US20160194290A1 (en) 2016-07-07
JP2022116239A (ja) 2022-08-09
KR102551018B1 (ko) 2023-07-05
EP3231793B1 (en) 2020-03-11
HRP20200584T1 (hr) 2020-07-10
PH12017501071A1 (en) 2017-12-18
ME03760B (me) 2021-04-20
LT3231793T (lt) 2020-04-27
AU2015362394B2 (en) 2020-07-02

Similar Documents

Publication Publication Date Title
CO2017005732A2 (es) Compuestos de dihidropirimidin-2-ona y sus usos médicos
BR112017008659A2 (pt) ?métodos e compostos de agonista de gip?
TWD179642S (zh) 腕錶
TWD173411S (zh) 項鍊
EA201790785A1 (ru) Производные тетрагидроизохинолина
UY36499A (es) Uso de picolinamidas como fungicidas
CR20160044S (es) Dispensador de jabon
UY35274A (es) Compuestos y métodos para tratar infecciones bacterianas
TWD174677S (zh) 手錶
MA46284A (fr) Canule cardiaque
EA201691887A1 (ru) Лечение внутрипеченочных холестатических заболеваний
DK3097085T3 (da) Benzoxazinonderivater til behandling af hudsygdomme
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
DK3452100T3 (da) FARMACEUTISKE BÆRERE INDEHOLDENDE miRNAer TIL ANVENDELSE I BEHANDLINGEN AF FIBROTISKE SYGDOMME FORÅRSAGET AF HYPERGLYKÆMI
DK3151814T3 (da) Behandling af en hudlæsion
ECSP16096831A (es) Derivados de naftiridinadiona
UY34543A (es) Derivados de sulfonilaminopirrolidinona, su preparación y aplicación terapéutica.
EA201790526A1 (ru) Фармацевтические комбинации ситаглиптина
DOP2017000016A (es) Nueva sal de disoproxilo de tenofovir
RU2014115406A (ru) Применение 8-(трифторметил)бензо[f][1,2,3,4,5]пентатиепин-6-амина в качестве антидепрессанта
TWD180406S (zh) 拋棄式尿布
CR20150229S (es) Modelo industrial de caseta para baño
TWD173934S (zh) 血壓計
TWD173435S (zh) 土除
TWD178255S (zh) 齒間刷